Patents by Inventor Anne-Marie Beausoleil

Anne-Marie Beausoleil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210401808
    Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
    Type: Application
    Filed: May 14, 2021
    Publication date: December 30, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
  • Publication number: 20210379078
    Abstract: This invention is based on the discovery that inhibiting more than one pathway in senescent cells leading to apoptosis has a profound effect: namely, increasing the potency or the cell specificity of the therapy. Combining a Bcl inhibitor with an Mcl 1 inhibitor increases the ability of the Bcl inhibitor to remove senescent cells from the site of an adverse condition synergistically. This increases the types of senescent cells that can be targeted, broadens the therapeutic range, and allows the user to tailor a particular combination of agents by adjusting the molar ratio for the patient being treated. Suitable indications for treatment may include any condition thought to be mediated at least in part by senescent cells, such as ophthalmic conditions, pulmonary conditions, and atherosclerosis.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 9, 2021
    Inventors: Pieter Bas Kwak, Scott Armstrong, Pedro Beltran, Anne-Marie Beausoleil
  • Patent number: 11110095
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: September 7, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto, Xiaojun Huang
  • Patent number: 11033533
    Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: June 15, 2021
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
  • Patent number: 11008314
    Abstract: Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: May 18, 2021
    Assignee: Corvus Pharmaceuticals, Inc.
    Inventors: Ryan Hudson, Anne-Marie Beausoleil
  • Publication number: 20210130351
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 6, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • Patent number: 10981892
    Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: April 20, 2021
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20210070788
    Abstract: This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. The phospholidine compounds can include a P-phenyl phospholidine moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phospholidine moiety can be optionally substituted at phosphorus with thio (?S) instead of oxo (?O). A second heteroatom attached to phosphorus can be cyclically linked to the N-substituted nitrogen atom of the phospholidine that is attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Application
    Filed: July 2, 2020
    Publication date: March 11, 2021
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20200399259
    Abstract: This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. Phosphonamidate compounds typically include a P-phenyl phosphonamidate moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phosphonamidate moiety may be optionally substituted at phosphorus with thio (?S) instead of oxo (?O), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus may be cyclically linked to the N-substituted nitrogen atom that is attached to the phosphorus to provide a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety, a favorable binding conformation may be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 24, 2020
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 10870652
    Abstract: Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 22, 2020
    Assignee: CORVUS PHARMACEUTICALS, INC.
    Inventors: Ryan Hudson, Anne-Marie Beausoleil, Richard A. Miller, Erik Verner
  • Publication number: 20200392105
    Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 17, 2020
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20200360386
    Abstract: Senescent cell medicine encompasses the paradigm that many conditions that are associated with aging or tissue damage are caused or mediated by senescent cells. This disclosure shows that HSP90, pI3-kinase, proteasome, HDAC, and p97 pathways are all active in senescent cells, and can be used as an effective means for removing senescent cells from a target tissue. Exemplary inhibitors of each of these pathways are provided. Also provided is a new genus of p97 inhibitor molecules. The structure includes a core 4 amino pyrimidine ring system, substituted at the 2 position with a nitrogen atom of an amino substituent or a N heterocycle. The 4 amino substituent of the core ring system is optionally linked to a substituted phenyl group. Any of the inhibitors referred to in this disclosure can be screened for senolytic activity and developed for the treatment of conditions such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Application
    Filed: December 28, 2018
    Publication date: November 19, 2020
    Inventors: Ryan Hudson, Anne-Marie Beausoleil, Remi-Martin Laberge
  • Publication number: 20200354336
    Abstract: This invention is based on the discovery that many lung diseases associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The severity of age-related conditions typically correlates with the abundance of senescent cells: thus, clearing senescent cells can help abrogate the condition: providing symptomatic relief, and potentially inhibiting disease progression. In accordance with this invention, a family of Bcl protein inhibitors has been developed for the treatment of lung diseases. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable pulmonary diseases.
    Type: Application
    Filed: August 13, 2018
    Publication date: November 12, 2020
    Inventors: Nick Vlahakis, Scott Armstrong, Jamie Dananberg, Ryan Hudson, Anne-Marie Beausoleil, Nathaniel David, Remi-Martin Laberge
  • Publication number: 20200317640
    Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
    Type: Application
    Filed: June 10, 2020
    Publication date: October 8, 2020
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20200281900
    Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
    Type: Application
    Filed: December 16, 2019
    Publication date: September 10, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
  • Patent number: 10745429
    Abstract: This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold, as shown in Formula (I). The phospholidine compounds can include a P-phenyl phospholidine moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phospholidine moiety can be optionally substituted at phosphorus with thio (?S) instead of oxo (?O). A second heteroatom attached to phosphorus can be cyclically linked to the N-substituted nitrogen atom of the phospholidine that is attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: August 18, 2020
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 10738042
    Abstract: This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold, as shown in Formula (I): Phosphonamidate compounds disclosed herein typically include a P-phenyl phosphonamidate moiety which is substituted with an N-aryl or N-heteroaryl group. The P-phenyl phosphonamidate moiety may be optionally substituted at phosphorus with thio (?S) instead of oxo (?O), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus may be cyclically linked to the N-substituted nitrogen atom that is attached to the phosphorus to provide a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety, a favorable binding conformation may be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: August 11, 2020
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 10717722
    Abstract: The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Compounds of this invention include compounds according to formula (I): Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: July 21, 2020
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Patent number: 10703745
    Abstract: This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. Acyl phosphonamidate compounds may include a P-phenyl phosphonamidate moiety which is N-acylated with an aroyl or heteroaroyl group. The P-phenyl phosphonamidate moiety can be optionally substituted at phosphorus with thio (?S) instead of oxo (?O), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus can be cyclically linked to a carbon atom of the adjacent phenyl ring attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 7, 2020
    Assignee: Unity Biotechnology, Inc.
    Inventors: Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20200199103
    Abstract: This invention is based on the discovery that many lung diseases associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The severity of age-related conditions typically correlates with the abundance of senescent cells: thus, clearing senescent cells can help abrogate the condition: providing symptomatic relief, and potentially inhibiting disease progression. In accordance with this invention, a family of Bcl protein inhibitors has been developed for the treatment of lung diseases. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable pulmonary diseases.
    Type: Application
    Filed: August 13, 2018
    Publication date: June 25, 2020
    Inventors: Nick Vlahakis, Scott Armstrong, Jamie Dananberg, Ryan Hudson, Anne-Marie Beausoleil, Nathaniel David, Remi-Martin Laberge